-
LG 101506: RXR Modulator Workflow Guide
2026-09-22
Build reproducible RXR signaling experiments with LG 101506 using staged dose–time testing, orthogonal transcriptional and protein readouts, and practical controls. The guide also shows how to use the compound to formulate, but not overstate, hypotheses connecting nuclear receptor signaling with immune-checkpoint biology in triple-negative breast cancer.
-
Cyclic di-GMP: From Biofilm Timing to STING
2026-09-22
Cyclic di-GMP is an intracellular second messenger that links early biofilm persistence mechanisms with STING-focused immune modulation research. This article presents an assay-centered framework for separating bacterial antitoxin biology from mammalian STING agonism and choosing more informative experimental controls.
-
D-Luciferin: From Brain Tumor Signal to Strategy
2026-09-21
A mechanistic and translational framework for using D-Luciferin potassium salt in longitudinal tumor studies, with particular emphasis on EGFR-mutant NSCLC brain metastasis models, assay design, and evidence-based interpretation.
-
HABA: Avidin–Biotin Assay Reagent
2026-09-21
HABA, or 4-hydroxyazobenzene-2-carboxylic acid, is a chromogenic ligand for avidin and streptavidin binding assays. Its absorbance response supports biotin accessibility measurements, but it does not replace particle sizing, surface-charge analysis, or HPLC-based drug-release testing.
-
Recombinant Human EGF in MYC-TNBC Assays
2026-09-20
Use recombinant human EGF as a controlled EGFR stimulus, assay benchmark, and culture-variable when investigating proliferation or drug sensitivity in MYC-driven triple-negative breast cancer models. This workflow connects product-quality controls with the EphA2 synthetic-lethality findings reported in a recent chemogenetic screen without implying that EGF itself is an EphA2 inhibitor.
-
HyperScribe Co-transcription mRNA Synthesis Kit Plus
2026-09-19
Generate ARCA-capped, template-polyadenylated mRNA for translation, vaccine, RNAi, and RNA structure studies. This practical guide connects reaction setup and troubleshooting with the design logic of a GPC3-HSP70 nanovaccine study.
-
Pregnancy, LNP Structure, and mRNA Outcomes
2026-09-19
This PNAS study shows that mRNA-LNP performance during pregnancy depends jointly on nanoparticle structure and administration route. Its findings connect ionizable-lipid design and IL-1β-associated inflammation with maternal expression, placental immune responses, and postnatal pup growth, offering a mechanism-based framework for safer pregnancy-focused RNA delivery.
-
ATP Solution: Energy Control in mRNA-LNP Research
2026-09-18
ATP Solution (100 mM) can improve interpretability across transcription, ligation, kinase, and phosphorylation workflows supporting mRNA-LNP research. This article connects ATP control to the localized p21 mRNA delivery strategy reported for bladder cancer while distinguishing assay-enabling reagents from therapeutic effects.
-
PLGA Microspheres for Controlled Cartilage Delivery
2026-09-17
A 2026 Pharmaceutics study shows that PLGA microsphere size, surface chemistry, and corticosteroid stability jointly determine delivery behavior in cartilage. Its key advance is distinguishing apparent mathematical diffusion from steric-limited transport while demonstrating that PEGylation can preserve hydrocortisone-17-butyrate during prolonged release.
-
Genotyping Kit for Target Alleles: Practical Workflows
2026-09-17
Build faster PCR genotyping workflows for insects, tissues, fishes, and cultured cells without phenol extraction or spin-column purification. This single-tube approach is especially useful for screening experimental animals and cell models linked to intestinal barrier studies, including genotype-defined E-cadherin research.
-
Vitamin D, RAF1, and mTOR in Juvenile Epilepsy
2026-09-16
A 2024 Neurochemical Research study identified RAF1-linked mTOR activation as a mechanism through which vitamin D reduced seizure severity, hippocampal inflammation, and neuronal apoptosis in juvenile epilepsy models. Its combined use of pilocarpine and glutamate models, network pharmacology, molecular docking, and rapamycin-based pathway validation offers a useful framework for studying mTOR-dependent neuroprotection.
-
Psoralen-Induced Cholestasis via ERK1/2
2026-09-16
Chen et al. showed that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, produce cholestatic liver injury in zebrafish larvae through ERK1/2 activation. By combining estrogenic, hepatobiliary, gene-expression, and pharmacological rescue assays, the study identifies ERK1/2 as a mechanistically testable node in phytoestrogen-induced cholestasis.
-
Pomalidomide (CC-4047) Research Workflows
2026-09-15
Use Pomalidomide (CC-4047) to connect cytokine modulation, genotype-aware myeloma models, and erythroid readouts in a disciplined research workflow. This guide emphasizes model selection, executable assay parameters, compound handling, and troubleshooting rather than treating one concentration or cell line as universally predictive.
-
HABA (4′-Hydroxyazobenzene-2-carboxylic acid)
2026-09-15
This scenario-based guide explains how HABA (4′-Hydroxyazobenzene-2-carboxylic acid), SKU B7918, can strengthen avidin–biotin surface characterization alongside cell viability, proliferation, and PLGA release workflows. It separates validated product facts from practical assay recommendations and shows how to interpret absorbance data without treating HABA as a substitute for a viability readout.
-
ARCA EGFP mRNA for Reliable Transfection Assays
2026-09-14
Learn how ARCA EGFP mRNA, SKU R1001, helps separate delivery and expression variability from true cytotoxicity in mammalian cell assays. This scenario-based guide covers reporter selection, handling, protocol optimization, data interpretation, and practical vendor evaluation.